Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
Tac-positive, HTLV-negative, T helper phenotype chronic lymphocytic leukemia cells.
Blood. 1985 Jun;65(6):1531-7. Unique Identifier : AIDSLINE MED/85200313 Pandolfi F; De Rossi G; Ranucci A; Bonomo G; Pasqualetti D; Napolitano M; Manzari V
Abstract:
In this report we describe an Italian patient with chronic T cell leukemia whose proliferating cells were mature T lymphocytes with a helper phenotype (T helper phenotype chronic lymphocytic leukemia, or Thp-CLL). Unlike other reported cases of Thp-CLL, fresh leukemic cells from this patient were positive with the anti-Tac monoclonal antibody, which recognizes the receptor for interleukin-2 (IL-2). Thus, the phenotype of these cells was similar to that expressed by Japanese patients with adult T cell leukemia (ATL) (OKT3+, OKT4+, OKT8-, Tac+). However, the Italian patient had Thp-CLL, not ATL, since his cells, unlike ATL cells, lacked human T cell leukemia virus (HTLV-I)-related DNA sequences. The Tac receptor, which appears to be modulated in vitro by the anti-Tac antibody, was biologically inactive, since the patient's cells did not respond in vitro to IL-2. In addition, they also failed to demonstrate in vitro functional activities. The clinical course was aggressive, as usual, for both Thp-CLL and ATL. Taking advantage of the description of this case, some similarities and differences between Thp-CLL and ATL are discussed, focusing on the importance of screening of HTLV-I in the differential diagnosis.
Keywords: Aged Antigens, Surface/*ANALYSIS Case Report DNA, Viral/ANALYSIS Human *HTLV-BLV Viruses/GENETICS Interleukin-2/BIOSYNTHESIS Leukemia, Lymphocytic/*IMMUNOLOGY/MICROBIOLOGY Lymphocyte Transformation Male Phenotype Phytohemagglutinins/PHARMACOLOGY Support, Non-U.S. Gov't T-Lymphocytes, Helper-Inducer/*IMMUNOLOGY JOURNAL ARTICLE
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.